GeNeuro Announces First Patient Treated in Phase 2a Study with GNbAC1 in Type 1 Diabetes
Geneva, Switzerland, 19 June 2017 - 7:30am CEST : - GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that the first patient ha ...